Fast Market Research

Boston, MA -- (SBWIRE) -- 07/14/2012 -- The non-small cell lung cancer pipeline is growing as a result of an increased understanding of the disease's heterogeneity, which has led to the development of personalized therapies targeting distinct patient subtypes. The success of these personalized therapies is likely to incentivize pharmaceutical companies to continue developing targeted therapies for niche patient populations.

Pipeline drugs such as Bristol-Myers Squibb's Erbitux (cetuximab) and Roche's MetMab (onartuzumab) are currently being trialed in combination with platinum chemotherapy and Avastin respectively. Roche will inevitably benefit if MetMab is approved in this setting given Avastin's already established physician familiarity and high uptake.

Targeted therapies maintain competition for greater market share. Avastin remains dominant, particularly in the US, but Tarceva (erlotinib), Iressa (gefitinib) and Xalkori (crizotinib) will increase pressure on Avastin given that their use in specific patient subsets avoids exposing unsuitable patients to unnecessary side-effects.

Targeted and immunotherapeutic drugs dominate the late-stage pipeline. Lucanix (belagenpumatucel-L) and Stimuvax (BLP-25) are the most advanced immunotherapies in the pipeline, looking set to enter the market in the second-line and maintenance settings respectively. No immunotherapies are currently approved for non-small cell lung cancer

Reasons to Get this Report

- Understand the dynamics of non-small cell lung cancer therapy and identify the market leaders in this competitive indication.
- Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy.
- Understand how pipeline drugs will be used with current therapies and how the market is accessed through less competitive treatment settings.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.